# Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma

> **NCT05416073** · PHASE4 · UNKNOWN · sponsor: **The Second Affiliated Hospital of Chongqing Medical University** · enrollment: 70 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Transarterial Chemoembolization
- Hepatic Arterial Infusion Chemotherapy
- Pain

## Interventions

- **DRUG:** Esketamine
- **DRUG:** Sufentanil

## Key facts

- **NCT ID:** NCT05416073
- **Lead sponsor:** The Second Affiliated Hospital of Chongqing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-22
- **Primary completion:** 2023-04-30
- **Final completion:** 2023-04-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2023-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05416073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05416073, "Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05416073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*